# Omalizumab

## Xolair inj 150mg/1.2mL

| 藥物代碼           | IXOL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | --Treatment of moderate to severe persistent asthma in adults and adolescents 12 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.--Chronic idiopathic urticaria: Treatment of chronic idiopathic urticaria in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 副作用             | >10%: Central nervous system: Headache (6% to 12%)1% to 10%:Cardiovascular: Peripheral edema (>2%)Central nervous system: Anxiety (>2%), migraine (>2%) Dermatologic: Alopecia (>2%)Gastrointestinal: Toothache (>2%)Genitourinary: Urinary tract infection (>2%)Infection: Fungal infection (>2%)Local: Injection site reaction (3%)Neuromuscular & skeletal: Arthralgia (3%), limb pain (>2%), musculoskeletal pain (>2%), myalgia (>2%) Respiratory: Nasopharyngitis (9%), sinusitis (5%), upper respiratory tract infection (3%), asthma (>2%), oropharyngeal pain (>2%), sinus headache (>2%), cough (2%), viral upper respiratory tract infection (<2%)Miscellaneous: Fever (>2%)All indications: <1% (Limited to important or life-threatening): Alopecia, anaphylaxis, antibody development, arthritis, chest tightness, Churg-Strauss syndrome, lymphadenopathy, malignant neoplasm, pulmonary hypertension, syncope, thrombocytopenia, transient ischemic attacks |
| 禁忌               | Hypersensitivity reaction to omalizumab or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 藥物保存方式       | 2-8 ℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 用法用量           | Dosing: Adult Allergic asthma 75-600 mg in 1-4 SC inj. Max: 600 mg every 2 week. Chronic spontaneous urticaria 300 mg SC every 4 week. Chronic idiopathic urticaria: SubQ: 150 or 300 mg every 4 weeks. Dosing is not dependent on serum IgE (free or total) level or body weight.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 肝功能異常         | 無需調整劑量  There are no dosage adjustments provided in the manufacturer's                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 懷孕用藥危分級     | 可能安全                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 注射劑給藥建議途徑 | SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 乾粉稀釋液         | 使用所附稀釋溶液                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 注意事項           | 1.本藥僅供單次使用的小瓶，配製後藥品於2℃至8℃可放置8 小時，於30℃下為4 小時。 2.以配備有大內徑18 號針頭，自安瓿中抽1.4 毫升注射用水，並注入omalizumab 小瓶中。 3. 將小瓶保持直立，不停地旋轉直立小瓶（不可上下搖動），凍晶乾粉完全溶解可能花費超過20 分鐘。配製後藥品為澄清或些許不透明感。若有異物即不可使用。 4. 以 25 號針頭進行皮下注射。排除氣體、大氣泡及多餘的溶液，此注射小瓶含1.2 毫升（150 毫克）的喜瑞樂。因溶液較粘稠，注射需5-10 秒。 5. 於手臂或大腿的三角肌區域進行皮下注射，避開蕁麻疹病灶處。                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

## Xolair inj 150mg/1.2mL (sample)

| 藥物代碼           | IXOL0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症             | --Treatment of moderate to severe persistent asthma in adults and adolescents 12 years and older who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.--Chronic idiopathic urticaria: Treatment of chronic idiopathic urticaria in adults and adolescents 12 years and older who remain symptomatic despite H1 antihistamine treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 副作用             | >10%: Central nervous system: Headache (6% to 12%)1% to 10%:Cardiovascular: Peripheral edema (>2%)Central nervous system: Anxiety (>2%), migraine (>2%) Dermatologic: Alopecia (>2%)Gastrointestinal: Toothache (>2%)Genitourinary: Urinary tract infection (>2%)Infection: Fungal infection (>2%)Local: Injection site reaction (3%)Neuromuscular & skeletal: Arthralgia (3%), limb pain (>2%), musculoskeletal pain (>2%), myalgia (>2%) Respiratory: Nasopharyngitis (9%), sinusitis (5%), upper respiratory tract infection (3%), asthma (>2%), oropharyngeal pain (>2%), sinus headache (>2%), cough (2%), viral upper respiratory tract infection (<2%)Miscellaneous: Fever (>2%)All indications: <1% (Limited to important or life-threatening): Alopecia, anaphylaxis, antibody development, arthritis, chest tightness, Churg-Strauss syndrome, lymphadenopathy, malignant neoplasm, pulmonary hypertension, syncope, thrombocytopenia, transient ischemic attacks |
| 禁忌               | Hypersensitivity reaction to omalizumab or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 藥物保存方式       | 2-8 ℃                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 用法用量           | Dosing: Adult Allergic asthma 75-600 mg in 1-4 SC inj. Max: 600 mg every 2 week. Chronic spontaneous urticaria 300 mg SC every 4 week. Chronic idiopathic urticaria: SubQ: 150 or 300 mg every 4 weeks. Dosing is not dependent on serum IgE (free or total) level or body weight.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 肝功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 腎功能異常         | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 懷孕用藥危分級     | 可能安全                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 孕期用藥建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 哺乳期用藥建議     | No (Limited) Human Data - Potential Toxicity 無(很少)資料 - 避免使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 附帶說明           | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 注射劑給藥建議途徑 | SC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 乾粉稀釋液         | 使用所附稀釋溶液                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 輸注點滴液         | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IVP 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IVD 用法建議       | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 注意事項           | 1.本藥僅供單次使用的小瓶，配製後藥品於2℃至8℃可放置8 小時，於30℃下為4 小時。 2.以配備有大內徑18 號針頭，自安瓿中抽1.4 毫升注射用水，並注入omalizumab 小瓶中。 3. 將小瓶保持直立，不停地旋轉直立小瓶（不可上下搖動），凍晶乾粉完全溶解可能花費超過20 分鐘。配製後藥品為澄清或些許不透明感。若有異物即不可使用。 4. 以 25 號針頭進行皮下注射。排除氣體、大氣泡及多餘的溶液，此注射小瓶含1.2 毫升（150 毫克）的喜瑞樂。因溶液較粘稠，注射需5-10 秒。 5. 於手臂或大腿的三角肌區域進行皮下注射，避開蕁麻疹病灶處。                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

